Dr. Denise Yardley on the Challenges in Treating Triple Negative Breast Cancer
Denise Yardley, MD, says one of the biggest challenges the malignancy poses is triple negative breast cancer's heterogeneity, resulting in medical professionals having to rely on clinical path features that do not provide enough preciseness in treatment.
Denise Yardley, MD, a medical oncologist at the Sarah Cannon Cancer Research Institute in Nashville, Tennessee, discusses the challenges of treating triple negative breast cancer. Yardley says one of the biggest challenges the malignancy poses is triple negative breast cancer's heterogeneity, resulting in medical professionals having to rely on clinical path features that do not provide enough preciseness in treatment.
Yardley adds that one of the keys to treating triple negative breast cancer is to segregate out different types of tumors that would respond to certain treatments. She also says that label "triple negative breast cancer" is not a "one-size-fits-all" type of breast cancer, and needs to be further explored by researchers.
Roundtable Roundup: Adjuvant Therapy for HR+, HER2- Breast Cancer
June 17th 2025In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast cancer to potentially receive hormonal plus endocrine therapy.
Read More
